CryoLife, Inc. (CRY)

28.80 -0.19 (-0.66%) As of 11:27AM EDT. Market open.

CryoLife, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
http://www.cryolife.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 1,200

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Patrick Mackin	Chairman, Pres & CEO	1.09M	N/A	1967
Mr. David Ashley Lee CPA, CPA	Exec. VP, COO & CFO	579.08k	217.16k	1965
Ms. Jean F. Holloway Esq.	Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.	476.26k	176.18k	1957
Mr. John E. Davis	Sr. VP of Global Sales & Marketing	436.39k	N/A	1965
Ms. Amy D. Horton CPA, CPA	VP & Chief Accounting Officer	N/A	N/A	1970
Mr. Matthew A. Getz	VP of HR	N/A	N/A	1969
Joshua Wells	Sr. Director of Bus. Devel.	N/A	N/A	N/A
Dr. Marshall S. Stanton	Sr. VP of Clinical Research & Chief Medical Officer	N/A	N/A	N/A
Karen K. Dabbs	Assistant Corp. Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Corporate governance

CryoLife, Inc.’s ISS governance QualityScore as of 30 April 2021 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.